GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2007

PTC and Spinal Muscular Atrophy Foundation Extend Agreement

  • PTC Therapeutics and the Spinal Muscular Atrophy Foundation agreed to expand their research collaboration to identify and characterized compounds to treat the disease.

    PTC will receive an additional $1.6 million in funding when certain milestone considerations are met.

    The partnerhip is focusing on candidates to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA.

    “By applying our proprietary technologies,” says Stuart W. Peltz, Ph.D., president and CEO of PTC, “we have made important progress in our efforts to identify treatments for SMA.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »